BioSpecifics Technologies (NASDAQ:BSTC) Rating Lowered to Sell at BidaskClub

BioSpecifics Technologies (NASDAQ:BSTC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday, BidAskClub reports.

BSTC has been the topic of a number of other reports. Zacks Investment Research raised BioSpecifics Technologies from a “strong sell” rating to a “strong-buy” rating and set a $72.00 price target on the stock in a research note on Tuesday, July 14th. HC Wainwright increased their target price on BioSpecifics Technologies from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th.

Shares of NASDAQ BSTC opened at $62.66 on Friday. The company has a market capitalization of $460.24 million, a PE ratio of 18.82 and a beta of 0.89. BioSpecifics Technologies has a twelve month low of $42.00 and a twelve month high of $69.51. The firm has a fifty day simple moving average of $62.82 and a 200 day simple moving average of $58.59.

BioSpecifics Technologies (NASDAQ:BSTC) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $0.73 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.76 by ($0.03). BioSpecifics Technologies had a return on equity of 21.37% and a net margin of 61.80%. The business had revenue of $9.67 million during the quarter, compared to the consensus estimate of $9.20 million. As a group, analysts anticipate that BioSpecifics Technologies will post 2.21 earnings per share for the current year.

Several institutional investors have recently modified their holdings of the company. Emerald Advisers LLC bought a new position in shares of BioSpecifics Technologies in the second quarter valued at approximately $25,000. Great West Life Assurance Co. Can purchased a new position in BioSpecifics Technologies during the 4th quarter worth $28,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of BioSpecifics Technologies by 92.5% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 666 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 320 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of BioSpecifics Technologies by 131.4% in the first quarter. Meeder Asset Management Inc. now owns 1,627 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 924 shares during the last quarter. Finally, Citigroup Inc. lifted its position in shares of BioSpecifics Technologies by 38.7% during the first quarter. Citigroup Inc. now owns 1,838 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 513 shares in the last quarter. 62.97% of the stock is owned by hedge funds and other institutional investors.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Recommended Story: The basics of gap trading strategies

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.